Compare TMDX & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | ALMR |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2019 | 2026 |
| Metric | TMDX | ALMR |
|---|---|---|
| Price | $86.30 | $34.79 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $148.22 | N/A |
| AVG Volume (30 Days) | ★ 623.7K | 284.2K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $605,494,000.00 | N/A |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $18.75 | N/A |
| P/E Ratio | $142.07 | ★ N/A |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $60.11 | $21.58 |
| 52 Week High | $156.00 | $38.54 |
| Indicator | TMDX | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 65.19 |
| Support Level | $80.29 | $23.69 |
| Resistance Level | $95.18 | $38.54 |
| Average True Range (ATR) | 4.40 | 2.16 |
| MACD | -0.41 | 0.15 |
| Stochastic Oscillator | 70.10 | 70.50 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.